Vyriad

Vyriad is a private, clinical-stage biotech developing a suite of targeted viral delivery platforms for genetic medicines and oncolytic virotherapy. Founded by Mayo Clinic scientists, the company leverages deep expertise in viral engineering, particularly with vesicular stomatitis virus (VSV) and measles virus backbones, to create therapies that directly target cells in the body. With active clinical trials in oncology and a partnership-driven business model, Vyriad aims to de-risk and advance novel treatments from preclinical development through manufacturing and early-phase clinical testing.

Engineered viral vector platforms based on vesicular stomatitis virus (VSV) and measles virus backbones, designed for cell-specific targeting, stability, and efficient delivery of genetic payloads for in vivo gene therapy, gene editing, and oncolytic virotherapy.

Vyriad competes in the crowded viral vector space against large gene therapy companies (e.g., Spark, uniQure), oncolytic virus developers (e.g., Amgen, Replimune), and numerous biotechs focused on novel delivery technologies for gene editing. Its differentiation hinges on its specific viral engineering for targeting and its integrated development model.